Vanguard Asset Management’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IBRX
Vanguard Asset Management's IBRX Position: Q3 2026 in Review
Vanguard Asset Management increased its ImmunityBio (IBRX) stake by 40% in Q3 2026, buying an estimated $844K and bringing the position to 372,654 shares worth $3.52M. The position accounts for ﹤0.01% of the portfolio, ranked #1255.
Vanguard Asset Management first reported a position in IBRX in Q1 2026 and has held it in 3 quarters since. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.
- Vanguard Asset Management held 372,654 shares of ImmunityBio worth $3.52M as of Q3 2026.
- Vanguard Asset Management bought 105,532 ImmunityBio shares in Q3 2026, an estimated $844K.
- ImmunityBio made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1255 holding.
- Vanguard Asset Management first reported a position in ImmunityBio in Q1 2026 and has held it in 3 quarters since.
- 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.
Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.